Clinical trials recruiting in Osaka, Japan

Phase breakdown

Conditions recruiting in Osaka, Japan

Recruiting trials in Osaka, Japan

• A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
  NCT07190248 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
  NCT07060807 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
  NCT07351045 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
  NCT07351058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07170150 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female)
• A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
  NCT06872125 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female)
• A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
  NCT07227857 · Phase: Phase 1, Phase 2 · Ages: 2 Years to 12 Years · Sex: All (male and female)
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
  NCT06868277 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
  NCT06692738 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
  NCT05211895 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
  NCT07250802 · Phase: Phase 3 · Ages: 4 Years to 17 Years · Sex: All (male and female)
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
  NCT07165028 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer
  NCT05939661 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer
  NCT07766018 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
  NCT07681089 · Phase: Phase 2 · Ages: 18 Years to 79 Years · Sex: Male
• A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
  NCT06226883 · Phase: Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female)
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
  NCT07005154 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male
• A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
  NCT07202546 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
  NCT06660394 · Phase: Phase 3 · Ages: 2 Years to 65 Years · Sex: All (male and female)
• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
  NCT06742723 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
  NCT06103864 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
  NCT07662135 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
  NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female)
• A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins
  NCT07634484 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07196748 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
  NCT06979375 · Phase: Phase 2 · Ages: 40 Years to 84 Years · Sex: All (male and female)
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07005128 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
  NCT06435429 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
  NCT06411249 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
  NCT05920356 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
  NCT06793215 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
  NCT06318169 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
  NCT05789082 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
  NCT05995964 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
  NCT06875310 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
  NCT06750094 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
  NCT06662786 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
  NCT06345729 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
  NCT07369011 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
  NCT07392190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
  NCT06598943 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
  NCT07099898 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
  NCT07196722 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
  NCT06926868 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
  NCT07577843 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07577856 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of KK2269 in Adult Participants With Solid Tumors
  NCT06266299 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
  NCT07012395 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
  NCT06567782 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
  NCT07438496 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
  NCT07098338 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
  NCT06803823 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
  NCT06810505 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female)
• A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
  NCT06672939 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female)
• A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
  NCT07202884 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female
• A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
  NCT06623422 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
  NCT03093116 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female)
• A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  NCT06312176 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  NCT06841354 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
  NCT05253651 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
  NCT07213674 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
  NCT07218146 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of ZW251 in Participants With Advanced Solid Tumors
  NCT07164313 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
  NCT07023289 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  NCT04928846 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
  NCT06312137 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
  NCT05711394 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
  NCT06819878 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
  NCT06929273 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
  NCT07063745 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06764485 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
  NCT06561386 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
  NCT07365241 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
  NCT07219173 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
  NCT07522073 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
  NCT07784725 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
  NCT06033950 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
  NCT06625060 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
  NCT06947941 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
  NCT04772079 · Phase: Phase 3 · Ages: 4 Years to 18 Years · Sex: All (male and female)
• A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
  NCT07409272 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
  NCT06617325 · Phase: Phase 3 · Ages: 16 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
  NCT06807424 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
  NCT07321873 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
  NCT06976203 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
  NCT06951698 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
  NCT06882785 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  NCT06430801 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
  NCT06979336 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
  NCT07221357 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
  NCT06948448 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
  NCT07662213 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
  NCT07761117 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
  NCT07650916 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
  NCT06867094 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
  NCT07753993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Showing 100 of 177 recruiting trials.

Common questions

How many clinical trials are recruiting in Osaka, Japan?

177 recruiting trials have at least one study site in Osaka, Japan.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.